Genmab A/S

NASDAQ:GMAB

Biotechnology

Healthcare
$50.97 -0.47%

-$0.12 today

Market cap
$31.43B
Beta
0.68
P/E (TTM)
18.7
EPS (TTM)
$13.36
52W Low $20.23High $35.43

Volume 2.96M

Average 1.85M

GMAB Total Equity

Shareholders' claim on the company's assets after all liabilities: total assets minus total liabilities.

Genmab A/SNASDAQ: GMAB

Total Equity · Q2 FY2026 · quarter ended Jun 2026

Total equity rises 12.4% from a year ago

Total equity stood at $5.96B at the end of Q2 FY2026, up 12.4% from a year earlier and up 4.8% from the prior quarter. Over 3 fiscal years it compounded at -40.2% a year.

Context

  • Total equity amounted to 47.6% of total assets at the end of Q2 FY2026, down 34.4 pp from a year earlier.
  • Total equity increased in 2 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether total equity keeps rising in the next quarterly balance sheet after a +12.4% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterJun 2026
$5.96B+4.8% QoQ
Last fiscal yearDec 2025
$5.83B-84.1% YoY
Year agoJun 2025
$5.3B+12.4% since
Total Equity past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+12.4%——
1 year-84.1%——
3-year CAGR-40.2%——
5-year CAGR——
10-year CAGR——

Total Equity history

Mixed currencies · from the balance sheet

Latest · FY2025
5.83B USD
Year-over-year change
—

Total Equity vs competitors

How GMAB compares with its peers on the latest reported figures

  • Peers report in different currencies, so total equity is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of +12.4% is the 6th highest of 11, against a peer median of +12.4%.
  • Total equity amounts to 47.6% of total assets for GMAB, versus a peer median of 75.0%.
GMAB Competitors
Total Equity for GMAB and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
BNTXBioNTech SEJun 2026€17.75B EUR-4.1%-1.4%87.3%
INCYIncyte CorporationJun 2026$6.34B USD+52.1%+5.7%80.6%
GMABGenmab A/SJun 2026$5.96B USD+12.4%-40.2%47.6%
EXELExelixis, Inc.Jul 2026$1.84B USD-9.3%-4.6%73.9%
LEGNLegend Biotech CorporationSep 2026$1.27B USD+25.9%+10.4%75.7%
IOVAIovance Biotherapeutics, Inc.Sep 2026$812.66M USD+15.7%+11.8%82.0%
RCUSArcus Biosciences, Inc.Jun 2026$464M USD-15.5%-1.3%50.2%
ALXOALX Oncology Holdings Inc.Mar 2026$151.35M USD+71.4%-53.8%84.9%
CGENCompugen Ltd.Mar 2026$95.35M USD+67.0%+9.8%65.4%
MGNXMacroGenics, Inc.Mar 2026$21.2M USD-73.2%-26.8%9.7%
ADCTADC Therapeutics S.A.Mar 2026-$216.38M USD+9.2%—74.2%
Peer median (excluding GMAB) —+12.4%-1.3%75.0%

Competitors are the stored peer set for GMAB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

Mixed currencies
Metric
FY2021
Dec 2021 · DKK
FY2022
Dec 2022 · DKK
FY2023
Dec 2023 · DKK
FY2024
Dec 2024 · DKK
FY2025
Dec 2025 · USD
Cash & Equivalents8.96B9.89B14.87B9.86B1.71B
Short-term Investments10.38B12.43B13.27B11.24B0
Net Receivables3.37B5.71B4.95B6.69B1.15B
Inventory0057M62M17.96M
Other Current Assets31M182M003
Total Current Assets22.74B28.22B33.14B27.85B2.88B
Property, Plant & Equipment (Net)975M1.32B1.64B263.83M279.36M
Goodwill0002.54B354.19M
Intangible Assets254M146M101M12.34B9.1B
Long-term Investments371M133M134M228M58.87M
Tax Assets00212M126.68M170.61M
Other Non-current Assets291M300M62M2.46B4
Total Non-current Assets1.89B1.9B2.15B17.96B9.97B
Total Assets24.63B30.12B35.29B45.81B12.84B
Account Payables350M0001.07B
Short-term Debt0000273M
Tax Payables0054M1.71B0
Deferred Revenue0033M24M23.95M
Other Current Liabilities860M1.75B00(663.92K)
Total Current Liabilities1.57B1.82B2.48B5.31B1.42B
Long-term Debt00005B
Deferred Tax Liabilities0002.36B363.17M
Deferred Revenue (Non-current)00480M480M94.78M
Other Non-current Liabilities500M491M35M30M5M
Total Non-current Liabilities863M1.01B1.2B3.81B5.59B
Total Liabilities2.43B2.84B3.68B9.11B7.01B
Common Stock66M66M66M66M9.98M
Retained Earnings10.02B14.81B19.02B23.55B4.09B
Accumulated OCI81M98M60M490M(180.59M)
Other Stockholders Equity00000
Minority Interest00000
Total Equity22.2B27.28B31.61B36.7B5.83B
Total Debt425M597M770M1.03B5.43B
Net Debt(8.53B)(9.3B)(14.1B)(8.83B)3.71B

Genmab A/S

NASDAQ:GMAB

Intrinsic Alpha fair value

Locked

Current Price

$50.97

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.